#ASCO26: AstraZeneca's triplet combo succeeds in liver cancer subgroup

AstraZeneca at #ASCO2026 (Karen Weintraub for Endpoints News) June 1, 2026 08:00 AM EDTUpdated 06:49 PM R&D As­traZeneca's triplet com­bo suc­ceeds in some liv­er can­cer pa­tients Max Gelman Senior Editor CHICA­GO — As­traZeneca on Mon­day re­port­ed da­ta from a new study show­ing the com­bi­na­tion of a tar­get­ed treat­ment and two im­munother­a­pies can ben­e­fit pa­tients with cer­tain … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER